Adicet's ADI-001 RA update tests cell therapy without conditioning
Adicet expects an H2-2026 update on ADI-001 in treatment-refractory rheumatoid arthritis, a Phase 1 safety study probing whether its gamma delta T cell therapy can work without lymphodepletion.
Executive Summary
- Adicet Bio has guided consistently toward a second-half 2026 clinical update for its Phase 1 rheumatoid arthritis cohort of ADI-001, and that timing has held steady across four separate disclosures.
- The trial is a dose-escalation safety study built to test whether ADI-001 can be given without the lymphodepleting conditioning regimen typically required for cell therapies, a design choice aimed at broadening how the therapy could eventually be used.
- A tolerability signal here would extend what Adicet has already reported in its lupus and lupus nephritis cohorts, where the same drug showed renal responses and a low rate of severe cytokine release syndrome, informing how the company positions ADI-001 across its broader autoimmune pipeline.
- No other program shares ADI-001's gamma delta T cell mechanism in rheumatoid arthritis, leaving the trial to be judged against its own dose-limiting-toxicity bar rather than against a direct rival's data.
The setup
Adicet Bio, Inc. is running a 25-patient Phase 1 dose-escalation trial of ADI-001 in treatment-refractory rheumatoid arthritis, registered as NCT07100873. The trial's primary endpoint is the incidence of dose-limiting toxicities within each dose cohort, a tolerability measure rather than an efficacy endpoint. The study started dosing patients in October 2025 and moved to Recruiting status in December 2025, after opening as Not Yet Recruiting. Its primary completion date is set for March 30, 2027, roughly nine months after the stated data-update window closes. NCT07100873A Phase 1 Study of ADI-001 in Rheumatoid ArthritisNCT07100873
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Why conditioning-free matters
Adicet has described this RA trial as distinct from its other ADI-001 autoimmune cohorts because it is exploring the potential to reduce or eliminate the need for conditioning, the chemotherapy regimen typically given before cell therapy infusions to allow the transplanted cells to engraft. Chief Executive Officer Chen Schor said the company is "exploring the potential to reduce or eliminate the need for conditioning with a separate Phase 1 trial of ADI-001 in treatment-refractory RA patients". If ADI-001 shows an acceptable dose-limiting-toxicity profile without conditioning, that would test a different tolerability and access question than Adicet's lupus, lupus nephritis, and systemic sclerosis cohorts, which use the therapy's standard regimen. AdicetAdicet Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNov 5, 2025
What the drug has shown elsewhere
In its lupus and lupus nephritis cohorts, Adicet reported that all seven patients dosed with ADI-001 through an August 31, 2025 data cutoff showed reductions in disease-activity scores, with three complete renal responses among five lupus nephritis patients and no cases of Grade 2 or higher cytokine release syndrome or neurotoxicity. That data used the standard conditioning approach. The RA cohort's update, expected in the same window, will show whether removing conditioning changes the safety profile Adicet has established in these earlier cohorts. AdicetAdicet Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNov 5, 2025
The timing signal
Adicet has repeated the same second-half-2026 timing guidance for this update across four disclosures dated November 2025, January 2026, March 2026, and May 2026, each naming the same July 1 to December 31, 2026 window. That consistency runs alongside a registry primary completion date of March 2027, later than the stated update window; a mid-trial clinical update ahead of full completion is a routine disclosure pattern for an actively enrolling Phase 1 program, not the trial's final readout. Adicet+1Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNov 5, 2025A Phase 1 Study of ADI-001 in Rheumatoid ArthritisNCT07100873
The competitive frame
No other trial in rheumatoid arthritis shares ADI-001's gamma delta T cell mechanism. The nearest modality precedents are AlloNK, an allogeneic NK cell therapy from Artiva Biotherapeutics in Phase 2 testing for B-cell-dependent rheumatologic disease, and two early Phase 1 cell therapy programs from Baylx and PersonGen. None targets the same cell type or shares ADI-001's target, so the RA readout will be judged against its own tolerability bar rather than a head-to-head comparator.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.